腹腔镜手术对明显早期子宫透明细胞癌女性的肿瘤学安全性:一项多中心回顾性队列研究
这项多中心回顾性队列研究纳入273例明显早期子宫透明细胞癌(UCCC)女性,比较腹腔镜与开腹手术分期的肿瘤学结局。中位随访31.0个月,两组3年无病生存率和总生存率均无显著差异,手术方式不是独立预后因素。作者认为对临床早期子宫透明细胞癌,腹腔镜分期在肿瘤学上是安全的,但需进一步前瞻性研究证实。
要点
- 273例明显早期UCCC患者中,腹腔镜与开腹分期的3年无病生存率无显著差异(HR 1.06,95%CI 0.72-1.58,p=.758)。
- 两组3年总生存率无显著差异(HR 1.06,95%CI 0.65-1.72,p=.823)。
- 手术分期方式不是OS(调整HR 1.29,95%CI 0.78-2.12,p=.321)和DFS(调整HR 1.11,95%CI 0.73-1.68,p=.621)的独立预后因素。
核心结论
- 对临床早期子宫透明细胞癌,腹腔镜分期在肿瘤学上是安全的;该结论需进一步前瞻性研究证实。
研究设计与样本
- 多中心回顾性队列研究,纳入4家中国教学医院的273例明显早期子宫透明细胞癌(UCCC)女性,所有患者均接受腹腔镜或开腹手术分期。
主要发现
- 中位随访31.0个月,开腹组与腹腔镜组的3年无病生存率分别为68.82%和64.27%,差异无统计学意义(HR 1.06,95%CI 0.72-1.58,p=.758)。
- 开腹组与腹腔镜组的3年总生存率分别为72.76%和73.46%,差异无统计学意义(HR 1.06,95%CI 0.65-1.72,p=.823)。
- 多因素分析显示,手术分期方式不是明显早期UCCC患者OS的独立预后因素(调整HR 1.29,95%CI 0.78-2.12,p=.321)。
- 多因素分析显示,手术分期方式不是明显早期UCCC患者DFS的独立预后因素(调整HR 1.11,95%CI 0.73-1.68,p=.621)。
临床怎么用
- 作者认为,对临床早期子宫透明细胞癌,腹腔镜分期在肿瘤学上是安全的。
- 作者指出该结论需进一步前瞻性研究证实。
局限性
- 原文指出该结论需进一步前瞻性研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To study the effect of different surgical approaches (laparoscopy and laparotomy) on the oncological outcomes of patients with apparent early-stage uterine clear cell carcinoma (UCCC). DESIGN: Retrospective cohort study. SETTING: Four Chinese teaching hospitals. PATIENTS: A total of 273 women with apparent early-stage UCCC. INTERVENTIONS: All included patients were surgically staged by laparoscopy or laparotomy. MEASUREMENTS AND MAIN RESULTS: The eligible patients were divided into the laparotomy group and the laparoscopy group. Disease-free survival (DFS) and overall survival (OS) were evaluated by the Kaplan-Meier method and compared by the log-rank test. The Cox proportional hazards regression model was used to estimate the adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the effect of surgical approach on DFS and OS. With a median follow-up of 31.0 months, the 3-year DFS rates were 68.82% and 64.27% in the laparotomy group and the laparoscopy group, respectively. The difference in DFS between the 2 groups was not statistically significant (HR, 1.06; 95% CI, 0.72-1.58; p = .758). In addition, the 3-year OS rate (72.76% vs 73.46%; HR, 1.06; 95% CI, 0.65-1.72; p = .823) was not different between the 2 groups. Furthermore, multivariable analysis showed that for patients with apparent early-stage UCCC, the approach of surgical staging was not an independent prognostic factor for OS (adjusted HR, 1.29; 95% CI, 0.78-2.12; p = .321) and DFS (adjusted HR, 1.11; 95% CI, 0.73-1.68; p = .621). CONCLUSION: For clinical early-stage clear cell carcinoma of the uterus, staging by laparoscopy is oncologically safe. This needs to be justified by further prospective studies.
引用
- Hu C, Mao XG, Xu Y, et al. Oncological Safety of Laparoscopic Surgery for Women with Apparent Early-stage Uterine Clear Cell Carcinoma: A Multicenter Retrospective Cohort Study. J Minim Invasive Gynecol. 2022. PMID: 35500748. doi:10.1016/j.jmig.2022.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。